Noubar Afeyan, Ph.D., is Co-Founder and Chairman of Tessera Therapeutics and Founder and CEO of Flagship Pioneering. Its research engine further optimizes the discovered candidates for efficiency, specificity, and fidelity-essentially compressing eons of evolution into a few months. The company has evaluated tens of thousands of natural and synthetic MGEs to create candidates with the ability to write therapeutic messages into the human genome. CAMBRIDGE, Mass.- ( BUSINESS WIRE )-Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicine known as Gene Writing technology, today announced the expansion. Tessera’s gene writer tools are based on nature’s genome architects, Mobile Genetic Elements (MGEs)-the most abundant class of genes across the tree of life, representing approximately half of the human genome. The platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Jun 28 10 years ago, the first publication on the gene-editing tech CRISPR changed the field.Led by Geoffrey von Maltzahn, Ph.D., Co-Founder, Chief Executive Officer, and Board Director, Tessera Therapeutics provides gene writing technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The company intends to use the funds to expand its development efforts. As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the definitive genetic medicine. Investors included Abu Dhabi Investment Authority (ADIA), Alaska Permanent Fund Corporation, Altitude Life Science Ventures, ARTIS Ventures, Cormorant Asset Management, Flagship Pioneering, Hanwha Impact Partners, Longevity Vision Fund, March Capital, SALT Fund, SoftBank Vision Fund 2, and T. Tessera Therapeutics, a Somerville, MA-based biotechnology company, raised over $300M in Series C funding.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |